References
- Eli Lilly and Company. Highlights of prescribing information: FORTEO. Available at: pi.lilly.com/us/forteo-pi.pdf [Last accessed 10 April 2015]
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
- Foster SA, Foley KA, Meadows ES, et al. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. Osteoporos Int 2008;19:373-7
- Boytsov N, Yu M, Sugihara T, Swindle R. Defining the teriparatide patient population: patient characteristics, osteoporosis sequence of care, and health care resources. Am J Pharm Benefits 2015;7:16-23
- Hansen LG, Chang S. Health research data for the real world: the MarketScan Databases, White Paper. Ann Arbor, MI: Truven Health Analytics, 2013
- Kemppainen T, Kroger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. Bone 1999;24:249-55
- Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease. Gut 2002;51:654-8
- van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol 2006;243(Suppl):59-64
- Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94
- Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9
- Wong M, Wan X, Ruff V, et al. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 2012;23:1445-52
- Deyo RA, Cherkin DC, Coil MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects, Biometrika 1983;70:41-55
- Austin P, Chiu M, Ko DT, et al. Propensity score matching for estimating treatment effects. In: Faries D, Leon A, Haro JM, Obenchain R, eds. Analysis of Health Care Data Using SAS. Cary, NC: SAS Institute Inc., 2010
- Hazel-Fernandez L, Louder AM, Foster SA, et al. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study. BMC Musculoskeletal Disord 2013;14:4
- Yu S, Burge RT, Foster SA, et al. The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 2012;23:1103-13
- Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014;161:711-23
- Epstein S, Cryer B, Ragi S, et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003;19:781-9
- Halkin H, Dushenat M, Silverman B, et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007;41:29-34
- Brooks J, Ohsfeldt R. Squeezing the balloon: propensity scores and unmeasured covariate balance. Health Serv Res 2013;48:1487-507
- The Henry J. Kaiser Family Foundation. State health facts online. Available at: http://kff.org/other/state-indicator/total-population/ [Last accessed 17 October 2014]